Market revenue in 2024 | USD 63,480.1 million |
Market revenue in 2030 | USD 90,646.8 million |
Growth rate | 6.1% (CAGR from 2025 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 57.56% in 2024. Horizon Databook has segmented the UK pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
The UK pharmaceutical market driven by rising healthcare spending on pharmaceutical products. In 2023, the UK’s healthcare expenditure was estimated at approximately USD 360.31 billion, reflecting a 5.6% nominal increase from the previous year.
However, after adjusting for inflation, total healthcare spending declined by 1.4%. Healthcare expenditure as a percentage of GDP slightly decreased to 10.9% from 11.1% in 2022, as economic growth outpaced healthcare spending. Government-funded healthcare expenditure accounted for around USD 294.92 billion, representing a real-term decline of 2.1%.
One of the most significant shifts in the sector was a 16.6% reduction in real-term pharmaceutical spending, primarily due to lower costs associated with the COVID-19 vaccination program. Meanwhile, long-term health and social care spending increased by 2.8%, underscoring the growing demand for sustained healthcare support, particularly for chronic conditions and aging-related care.
Horizon Databook provides a detailed overview of country-level data and insights on the UK pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into UK pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account